Type 2 diabetes mellitus — personalising management with non-insulin medications

Published on 17 May 2023
Last Updated on 17 May 2023

This ACE Clinical Guidance (ACG) focuses on optimising management of type 2 diabetes mellitus (T2DM) by personalising selection of non-insulin T2DM medications based on patient comorbidities and risk factors, in particular cardiovascular and renal factors.

This ACG replaces the 2017 ACG “Oral glucose-lowering agents in type 2 diabetes mellitus – an update”.

Download the ACG

T2DM – personalising management [PDF, 1.6 KB]

Request for a hardcopy

Click here

ACG Recommendations

1. Assess the patient’s glycaemic control and risk of adverse cardiorenal outcomes.

2. Select and adjust T2DM medication(s) based on the patient’s glycaemic control and their risk of adverse cardiorenal outcomes.

3. Consider metformin as first-line T2DM medication.

4. Consider prescribing an SGLT2 inhibitor or GLP-1 RA for patients with T2DM who need to reduce their risk of adverse cardiorenal outcomes.

5. Adopt a patient-centred approach to make shared decisions on T2DM management.

6. Educate patients with T2DM on sustained lifestyle intervention, medication adherence, and regular review.

7. Review all patients with T2DM regularly, including treatment response and complication screening.

ACG references and useful resources

Click below to see the list of references for the type 2 diabetes mellitus ACG and useful resources.

• T2DM – personalising management references [PDF, 145 KB]

• T2DM – personalising management useful resources [PDF, 10 KB}